NeOnc Technologies Inc. (NTHI)
NeOnc Technologies Inc. (NTHI) Stock Price, Analysis & Data
| Bid | 3.41 |
| Market Cap | 88.09M |
| Revenue (ttm) | 39.99K |
| Net Income (ttm) | -47.2M |
| Beta | n/a |
| EPS (ttm) | -2.12 |
| PE Ratio (ttm) | n/a |
| Forward PE | -4.51 |
| P/B (ttm) | -6.20 |
| P/S (ttm) | 2202.74 |
| Earnings Date | Nov 12, 2026 |
| Ask | 3.57 |
| Volume | 964,806 |
| Avg. Volume (20D) | 95,108 |
| Open | 4.49 |
| Previous Close | 4.35 |
| Day's Range | 3.30 - 4.74 |
| 52-Week Range | 3.00 - 12.99 |
| Analyst | n/a |
| Price Target | 15 (341.18%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NTHI
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatme...
Financial Performance
In 2025, NeOnc's revenue was 39.99K, a decrease of -51.82% compared to the previous year's 83K. Earnings were -62.15M, an increase of 422.3%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for NTHI stock is "null". The 12-month stock price forecast is 15, which is upside of 341.18% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
